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	Abstract	
	
Purpose	of	review:	This	review	summarises	recent	data	supporting	the	concept	
that	urinary	microRNAs	are	a	useful	new	class	of	biomarker.	They	may	improve	
capacity	to	stratify	patients	with	CKD	according	to	risk	of	progression,	and	may	
also	inform	about	response	to	therapy.		
Recent	 findings:	 MicroRNAs	 are	 present,	 stable	 and	 readily	 quantifiable	 in	
tissues	 and	 body	 fluids,	 including	 urine,	 and	 have	 widespread	 importance	 as	
regulators	 in	 the	 kidney.	 Urinary	 microRNAs	 are	 typically	 released	 from	 the	
nephron	 or	 downstream	 structures,	 and	 their	 abundance	 may	 reflect	 altered	
microRNA	 expression	 in	 the	 kidney,	 or	 release	 into	 the	 lumen	 by	 the	 cells	
comprising	the	different	regions	of	the	nephron.	As	a	consequence,	abundance	of	
specific	microRNAs	in	the	urine	may	change	in	various	pathological	states.	Large-
scale	 studies	 are	 now	 needed,	 to	 test	 the	 capacity	 of	 specific	 microRNAs	 to	
inform	about	risk	and	response	to	therapy.		
Summary:	 Urinary	 microRNAs	 appear	 useful	 sentinels	 for	 pathological	
processes	 occurring	 in	 the	 kidney	 and	 may	 enable	 a	 “personalised	 medicine”	
approach	to	the	management	and	stratification	of	renal	disease.	
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	Introduction	
Biological	 markers	 of	 disease	 have	 been	 studied	 for	 millennia.	 Hippocrates,	
credited	 with	 conceiving	 that	 diseases	 had	 natural	 rather	 than	 supernatural	
causes,	 reflected	 in	 his	 writing	 on	 indirect	 measurements	 of	 health	 such	 as	
evaluation	 of	 the	 patient’s	 breath	 or	 urine	 [1].	 “Biomarker”	 is	 a	 more	
contemporary	term,	defined	by	a	National	Institutes	of	Health	Working	Group	in	
1998	 as,	 "a	 characteristic	 that	 is	 objectively	 measured	 and	 evaluated	 as	 an	
indicator	of	normal	biological	processes,	pathogenic	processes,	or	pharmacologic	
responses	 to	 a	 therapeutic	 intervention".	 The	 requirement	 for	 objective	
measurement	 is	 key,	 since	 it	 allows	 comparison	 of	 values	 from	 different	
individuals	or	time	points.	Some	commonly	utilized	clinical	parameters	can	also	
be	considered	as	biomarkers,	 for	example	blood	pressure.	Other	biomarkers	 in	
routine	 use	 in	 the	 care	 of	 patients	with	 Chronic	Kidney	Disease	 (CKD)	 include	
measurements	 of	 excretory	 kidney	 function,	 most	 commonly	 in	 the	 form	 of	
serum	 creatinine	 concentration	 and	 extrapolated	 estimates	 of	 glomerular	
filtration	rate	(eGFR),	and	measurements	of	urinary	protein	excretion.	Figure	1	
depicts	potential	uses	of	biomarkers	in	the	nephrology	setting.	
	
There	 are	 two	 key	 goals	 for	 existing	 and	 future	 biomarkers:	 firstly,	 to	 stratify	
patients	according	to	risk	of	disease	progression	or	complications	(e.g.	likely	rate	
of	decline	in	kidney	function	or	risk	of	major	adverse	cardiovascular	event)	and,	
secondly,	 to	 identify	 surrogates	 that	 can	 be	 used	 to	 measure	 response	 to	
treatment	(e.g.	reduction	in	urinary	protein	excretion	following	pharmacological	
blockade	of	 the	 renin-angiotensin	 system).	 In	 these	 terms,	 existing	biomarkers	
are	useful	but	limited.	Existing	measures	of	excretory	kidney	function	have	well-
documented	inaccuracies	and,	by	measuring	loss	of	function	retrospectively,	do	
not	provide	data	on	the	current	activity	of	pathological	processes	in	the	kidney.	
Urinary	 protein	 excretion	 is	 a	 valuable	 marker	 of	 glomerular	 damage	 and	
informs	about	risk	of	progressive	decline	in	excretory	function,	but	is	not	specific	
for	these.		
	
Therefore,	new	biomarkers	are	needed.	Biomarkers	are	most	valuable	when	they	
correlate	 to	 a	 specific	 modifiable	 outcome,	 and	 are	 not	 simply	 a	 means	 of	
labeling	patients	with	a	disease.	The	discovery	of	 the	M-type	phospholipase	A2	
receptor	 as	 a	 target	 antigen	 in	 idiopathic	 membranous	 GN	 is	 an	 excellent	
example	 [2].	 	 In	 this	 case,	 advancement	 of	 molecular	 understanding	 in	 this	
disease	 has	 not	 only	 improved	 diagnostic	 distinction	 from	 secondary	
membranous	GN,	but	also	provides	serological	evidence	of	disease	severity.	This	
helps	identify	those	with	greatest	potential	to	benefit	from	immunosuppression	
–people	 who	 would	 previously	 have	 first	 undergone	 a	 period	 of	 potentially	
deleterious	“watchful	waiting.”[3].		
	
MicroRNAs	also	show	promise	as	a	new	class	of	biomarker	 in	CKD.	MicroRNAs	
were	first	discovered	as	a	mechanism	of	post-transcriptional	regulation	of	gene	
expression	 in	 the	 nematode	 C.	 elegans,	 and	 have	 since	 been	 found	 to	 have	
widespread	expression	and	importance.	They	are	present	in	all	human	cells	and	
are	 now	 linked	 to	 many	 physiological	 and	 pathological	 processes.	 A	 recent	
excellent	 review	 summarises	 our	 current	 knowledge	 about	 the	 role	 of	
microRNAs	in	renal	diseases	[4**].	
	MicroRNAs	 are	 stable	 in	 tissues,	 and	 resist	 degradation	 in	 pathological	
specimens.	They	can	be	measured	by	sensitive	molecular	techniques	that	employ	
nucleic	 acid	 amplification	 approaches,	 including	 Quantitative	 Reverse	
Transcription-quantitative	 Polymerase	 Chain	 Reaction	 (RT-qPCR)	 and	 Next	
Generation	Sequencing.	More	recently,	these	observations	have	been	extended	to	
body	 fluids,	 including	 urine.	 	 Figure	 2	 depicts	 the	 biogenesis	 of	 urinary	miRs,	
which	 are	 stabilized	 either	 by	 association	 with	 extracellular	 vesicles	 (EVs)	 or	
specialised	proteins	[5,	6].	The	significance	of	certain	miRs	being	located	in	EVs	
versus	 protein-bound	 in	 urine	 is	 not	 yet	 known.	 The	 origin	 of	 urinary	miRs	 is	
predominantly	 the	 nephron	 and	 downstream	 urinary	 tract	 [7],	 with	 limited	
reports	 of	 freely	 filtered	 miRs	 from	 the	 systemic	 circulation	 [8].	 Crucially,	
urinary	microRNA	concentrations	have	been	 found	to	associate	with	 important	
clinical	characteristics,	including	histopathological	diagnosis.	Therefore,	there	is	
considerable	 interest	 in	utilising	these	accessible,	non-invasive	and	informative	
biomarkers	in	the	context	of	renal	disease.	
	
Next,	we	consider	microRNAs	as	biomarkers	in	specific	types	of	kidney	disease.	
To	 this	 end,	 we	 highlight	 selected	 examples	 of	 recent	 studies	 that	 have	
progressed	our	understanding	of	miRs	in	kidney	disease	and	their	future	use	as	
biomarkers,	and	we	apologise	to	the	many	workers	in	this	field	whose	research	
we	have	not	been	able	to	highlight	due	to	lack	of	space.	
	
	
	
	Diabetic	Nephropathy	
Diabetic	 Nephropathy	 (DN)	 is	 the	 leading	 cause	 of	 end-stage	 renal	 failure	
worldwide.	 There	 is	 an	 unmet	 clinical	 need	 to	 improve	 the	 molecular	
understanding	 of	 this	 multifactorial	 disease,	 in	 order	 to	 establish	 new	
biomarkers	and	therapeutic	targets	alike.	The	consequent	focus	on	DN	has	led	to	
significant	 progress	 in	 elucidating	 the	 roles	 of	 miRs	 in	 molecular-cellular	
pathways	that	result	in	the	histological	hallmarks	of	DN.	The	complexity	of	their	
crosstalk	 is	 demonstrated,	 for	 example,	 by	 the	 apparently	 conflicting	 roles	 of	
miR-192	 as	 both	 anti-	 and	pro-fibrotic	mediator	 in	TGFβ-induced	 fibrosis	 [9*].	
Such	 detailed	 mechanistic	 miR	 analyses	 in	 models	 of	 renal	 pathology	 provide	
prime	data	for	biomarker	development,	as	discussed	below.	
	
Proteinuria	 is	 one	 of	 the	 most	 widely	 used	 biomarkers	 in	 CKD,	 with	 urinary	
albuminuria	 excretion	widely	 adopted	 in	 the	 diagnosis	 and	monitoring	 of	 DN.	
Albuminuria	serves	a	useful	purpose	in	assessing	the	integrity	of	the	glomerular	
filtration	 barrier	 (GFB)	 and	 is	 easily	 detectable	 in	 urine	 using	 inexpensive	
bedside	 tests.	 However,	 albuminuria	 has	 shortcomings,	 including	 that	 it	 is	
detectable	only	once	renal	damage	has	ensued,	and	that	 it	 is	not	specific	 to	DN	
[10].	 	Albuminuria	is	also	a	weak	prognosticating	tool	in	DN-	the	idiosyncrasies	
in	 its	 relationship	 to	clinical	progression	are	summarised	 in	a	 recent	article	by	
Alicic	et	al.	[11].	
	
Urinary	 miRs	 represent	 biomarkers	 with	 potential	 not	 only	 to	 augment	 the	
utility	 of	 albuminuria	 as	 a	 surrogate	 marker	 of	 GFB	 integrity,	 but	 may	 also	
predict	 the	 progression	 of	DN	before	 the	 onset	 of	 GFB	 breakdown.	 In	 a	 recent	
report,	 Mohan	 et	 al	 showed	 that	 urinary	 miR-451-5p	 was	 increased	 in	 the	
urinary	 exosomes	of	 diabetic	 rats	 three	weeks	prior	 to	 significant	 albuminuria	
and	 three	 weeks	 before	 histological	 changes	 of	 glomerulosclerosis	 and	
tubulointerstitial	 fibrosis	were	noted.	 Interestingly,	kidney	 tissue	expression	of	
miR-451-5p	 fell	during	 the	development	of	DN	[12**].	Thus	miRs	secreted	 into	
the	 urine	 by	 the	 injured	 nephron	 in	 the	 early	 stages	 of	 DN	 may	 be	 used	 not	
simply	to	denote	the	current	state	of	damage,	but	to	differentiate	those	patients	
likely	to	progress	to	DN	who	would	warrant	specialist	nephrology	surveillance.	
This	 represents	 a	 novel	 means	 of	 stratifying	 an	 ever-growing	 population	 of	
diabetic	patients.	
	
There	 is	 currently	 an	 increase	 in	 studies	 utilising	 urinary	 miR	 “biomarker	
panels”-	 multiple	 miRs	 measured	 in	 combination,	 to	 optimize	 diagnostic	
sensitivity	 and	 specificity	 [13]	 as	 well	 as	 being	 more	 widely	 informative	 of	
disease	 processes	 [14].	 In	 recent	 work,	 Kato	 et	 al	 describe	 a	 megacluster	 of	
nearly	40	microRNAs	coordinately	 increased	 in	 the	glomeruli	of	mouse	models	
of	DN	and	renal	cells	treated	with	diabetogenic	stimuli.	Using	synthetic	antisense	
oligonucleotides,	 these	researchers	were	able	 to	 inhibit	 the	host	 transcript	and	
decrease	expression	of	this	entire	cluster	of	miRNAs,	resulting	in	attenuation	of	
early	 DN	 features	 in	 vitro	 and	 in	 mice	 [15**].	 These	 data	 emphasise	 the	
coordinate	 regulation	of	miR	expression	and	downstream	actions,	 and	 support	
the	idea	that	use	of	multiple	miR	panels	may	be	an	effective	means	of	monitoring	
a	multifactorial	condition	like	DN.	However,	for	use	as	DN	biomarkers,	additional	
barriers	 to	 implementation	 in	 care	 pathways	 that	 might	 arise	 from	 the	
development	 of	more	 complex	 diagnostic	 assays	 and	methods	 of	 data	 analysis	
for	multiple	miRs	should	be	borne	in	mind.	
	
	
Acute	Kidney	Injury	(AKI)	
Given	the	high	prevalence	of	AKI	in	at-risk	populations	and	its	strong	association	
with	 mortality,	 biomarkers	 capable	 of	 stratifying	 AKI	 risk	 in	 specific	 patient	
cohorts	 are	 highly	 desirable.	 Animal	models	 representing	 a	wide	 range	 of	 AKI	
aetiologies	have	recently	been	used	to	identify	candidate	biomarkers.	
	
In	a	rat	model	of	contrast-induced	AKI	(CI-AKI),	increased	miR-188,	miR-30a	and	
miR-30e	were	detected	in	plasma.	Subsequent	analysis	replicated	these	findings	
in	 71	 patients	 who	 developed	 CI-AKI	 following	 coronary	 angiography	 or	
percutaneous	 coronary	 intervention.	 These	 miRNAs	 may	 therefore	 have	
potential	utility	as	early	CI-AKI	biomarkers	[17*].	
	
AKI	 is	a	 frequent	complication	of	major	cardiac	surgery,	and	 is	associated	with	
increased	 mortality	 and	 morbidity.	 In	 an	 analysis	 of	 115	 cardiac	 surgery	
patients,	 baseline	 miR-21	 abundance	 was	 reduced	 in	 the	 42	 patients	 that	
suffered	 post-operative	 AKI.	 Furthermore,	 those	 with	 AKI	 stage	 2/3	 had	
significantly	 increased	mortality	over	 the	2.9	year	 follow	up	period.	Therefore,	
Gaede	et	al	propose	serum	miR-21	as	a	biomarker	to	stratify	high-risk	patients	in	
this	context	[18*].		
	 	
Another	recent	focus	has	been	the	use	of	mesenchymal	stem	cells	in	the	repair	of	
renal	injury.	Zhu	and	co-workers	showed	that	bone	marrow	mesenchymal	stem	
cell	 treatment	 alleviated	 renal	 injury	 in	 a	 cisplatin-induced	 rat	 model	 of	 AKI.	
Upregulated	expression	of	miR-146b	was	seen	in	kidney	tissues	from	AKI	rats	in	
comparison	with	control	animals,	and	elevated	serum	miR-146b	was	detected	in	
early	 disease.	 Cisplatin	 treatment	 upregulated	 miR-146b	 expression	 in	 rat	
kidney	epithelial	cell	line	NRK-52E.	These	cells	were	protected	from	drug-induced	
apoptosis	by	knockdown	of	this	miR	and	consequent	derepression	of	ErB4	[18*].	
MiR-146b	may	 therefore	have	utility	 as	 an	early	AKI	biomarker,	 and	decreasing	
the	abundance	of	this	miR	has	possible	therapeutic	potential.	
	
Glomerulonephritis		
It	 has	 been	 suggested	 that	 the	 use	 of	 urinary	 miRs	 or	 other	 biomarkers	 as	 a	
“liquid	biopsy”	could	remove	the	requirement	 for	renal	biopsy	 in	patients	with	
various	 forms	of	 acute	glomerulonephritis	 (GN).	However,	 it	will	 be	hard	 for	 a	
biomarker	or	biomarker	panel	to	replace	the	rich	histopathological	data	derived	
from	a	tissue	biopsy,	and	we	instead	envisage	the	role	of	miR	biomarkers	in	this	
context	 as	 augmenting	 the	 use	 of	 invasive	 biopsy	 by	 a)	 identifying	 whom	 to	
biopsy	 and	 b)	 allowing	 regular	 surveillance	 of	 disease	 activity,	 including	
response	 to	 treatment.	 In	 these	 terms,	 miRs	 have	 recently	 been	 proposed	 as	
biomarkers	 in	 the	 diagnosis	 and	monitoring	 of	 patients	 with	 Focal	 Segmental	
Glomerulosclerosis	 [19,	 20],	 with	 miR-193a	 particularly	 well	 characterized	 as	
having	a	direct	role	in	a	mouse	model	of	this	disease	[21].		
	
In	 IgA	 Nephropathy	 (IgAN),	 Serino	 et	 al	 recently	 conducted	 a	 retrospective,	
international	multicenter	study	to	determine	the	sensitivity	of	miR	biomarkers.	
Combined	 serum	 levels	 of	 miR-148b	 and	 let-7b	 (regulators	 of	 IgA1	 O-
glycosylation)	 differentiated	 between	 healthy	 blood	 donors	 and	 patients	 with	
IgAN.	 Moreover,	 the	 miR	 signature	 was	 specific	 for	 IgAN	when	 tested	 against	
other	 glomerular	 diseases,	 and	 remained	 an	 independent	 predictor	 of	 IgAN	
irrespective	of	renal	function	or	corticosteroid	treatment	[22*].	
	
Renal	Cell	Carcinoma	and	other	malignancies	
The	first	definitive	link	between	miRs	and	pathology	was	made	by	Calin	et	al	in	
their	work	on	Chronic	Lymphocytic	Leukaemia	[23].	Since	then,	there	has	been	a	
strong	 trajectory	 in	 oncology	 of	 discoveries	 about	 fundamental	 mechanisms	
feeding	 through	 into	 greater	 capacity	 to	 stratify	 patients	 using	 the	 associated	
biomarkers,	including	miRs.	In	Renal	Cell	Cancer	(RCC)	specific	miRs	have	been	
found	 to	 function	 as	 oncogenes	 [24*]	 and	 tumour	 suppressor	 genes	 [25],	 and	
recent	 studies	 have	 linked	 miR	 expression	 and	 patient	 outcomes,	 including	
prediction	of	metastatic	disease	[26,	27],	treatment	response	to	sunitinib	[28-30]	
and	post-operative	recurrence	[31*].		
	
In	 oncology	 patients,	 recent	 reports	 show	 that	 changes	 in	miR	 expression	 can	
help	define	response	to	immunosuppressant	treatment	[32,	33].	Similar	studies	
have	not,	 to	our	knowledge,	been	done	yet	 in	patients	with	GN	and	other	non-
malignant	 renal	 diseases.	 We	 predict	 that	 such	 studies	 might	 demonstrate	
potential	 for	 miR	 quantification	 to	 predict	 response	 to	 immunosuppressant	
treatment,	thus	potentially	minimising	ineffective	exposure	of	patients	to	classes	
of	drugs	with	 a	 high	 inherent	 burden	of	 treatment.	 	 Such	 tools	may	ultimately	
assist	 clinicians	 in	 assessing	 the	 risk-benefit	 ratio	 of	 immunosuppressant	
treatment	in	complex	cases	of,	for	example,	lupus	nephritis	or	vasculitis.	
	
In	patients	with	RCC,	tissue	expression	of	miR-193b	at	the	time	of	nephrectomy	
has	been	found	to	predict	eGFR	at	12	months	[34].	Most	studies	in	this	area	have	
focused	 exclusively	 on	 tissue	miR	 expression,	 but	 a	 recent	 study	 by	 Butz	 et	 al	
demonstrates	 the	 potential	 of	 urinary	miRs	 in	 distinguishing	 between	patients	
with	clear	cell	renal	carcinoma	(ccRCC)	and	healthy	participants,	and	a	return	of	
aberrant	 urinary	 miR	 expression	 to	 normal	 following	 successful	 surgical	
intervention	[35].	
	
Whilst	 providing	 promising	 leads	 in	 individualising	 the	 management	 of	 RCC,	
these	 small	 studies,	 with	 a	 predominant	 profiling/sequencing	 focus,	 lack	 the	
large-scale	patient	recruitment	and	longitudinal	data	to	derive	adequate	power	
to	validate	these	miRs	as	robust	RCC	biomarkers.		
	
MicroRNAs	as	therapeutic	targets		
MicroRNAs	have	rapidly	progressed	 to	 the	point	of	being	 tested	as	 therapeutic	
targets,	 with	 a	 number	 of	 phase	 I	 clinical	 trials	 underway,	 predominantly	 in	
oncology.	 The	 most	 well	 established	 miR-based	 therapeutic	 agent	 in	 non-
malignant	 disease	 is	 miravirsen,	 a	 miR-122	 antagonist	 that	 blocks	 the	 viral	
replication	of	the	hepatitis	C	virus,	currently	in	phase	II	clinical	trials	[36,	37].	In	
Nephrology,	 anti-miR-21	 treatment	 is	 currently	 undergoing	 Phase	 II	 testing	 in	
patients	 with	 Alport	 syndrome	 (ClinicalTrials.gov	 identifier	 NCT02855268)	
[38*],	 based	 upon	 the	 antifibrotic	 effects	 of	 anti-miR-21	 seen	 in	 alpha3-chain	
Type	 IV	 collagen	 knockout	 mice	 [39].	 MiR-21	 has	 a	 well-characterised	
association	 with	 organ	 fibrosis	 via	 repression	 of	 PPARα-regulated	 signaling	
pathways	 in	 Fatty	 Acid	 oxidation,	 mitochondrial	 biogenesis,	 and	 anti-
inflammatory	signaling	[39].	It	is	noteworthy	that	the	antifibrotic	action	of	anti-
miR-21	 is	not	specific	 to	Alport	syndrome,	but	may	be	applicable	 to	many	CKD	
aetiologies.	This	emphasises	the	importance	of	understanding	the	processes	that	
change	as	a	consequence	of	altered	miR	expression,	and	not	just	seeing	miRs	as	
markers	 of	 disease.	 In	 this	 review,	 we	 have	 presented	 the	 advances	 in	 miR	
biomarkers	by	clinical	diagnosis,	but	 it	may	be	equally	appropriate	 to	describe	
the	 role	 of	 miRs	 in	 precise	 pathophysiological	 pathways,	 many	 of	 which	 are	
common	across	several	renal	diagnoses	that	come	under	the	umbrella	of	“CKD”-	
diseases	 dominated	 by	 proteinuria,	 immune	 complex	 deposition,	 tubular	
dysfunction	etc.	
	
Common	 to	 the	 above	 examples	 of	 clinical	 trials	 of	 anti-miRs	 is	 the	 prior	
elucidation	 of	 precisely	 what	 the	 miR	 is	 doing,	 through	 thorough	 molecular	
profiling	of	the	affected	pathway,	known	miR	targets	and	the	downstream	effects	
of	 target	 repression.	 We	 propose	 that	 the	 same	 approach	 will	 be	 useful	 in	
investigating	 miRs	 as	 biomarkers.	 The	 rapid	 advancement	 of	 sequencing	
technology	means	that	it	is	now	possible	to	generate	vast	amounts	of	data	from	
profiling	 even	 single	 cells-	 but	 taking	 this	 approach	 to	 selecting	 potential	miR	
biomarkers	 in	 isolation,	 without	 also	 understanding	 their	 role	 in	 disease	
mechanisms,	will	be	challenging	to	translate	into	a	validated	test	suitable	for	use	
in	 clinical	 practice.	 Characterization	 of	 miR	 actions	 at	 the	 molecular-cellular	
level,	 including	 identification	 of	 targets	 and	 downstream	 effects	 of	 target	
repression,	is	also	important.	
	
Conclusion	
MicroRNAs	 have	 significant	 potential	 as	 biomarkers	 in	 renal	 disease.	 The	
challenge	 is	 to	 translate	 this	 to	 clinical	 use.	 In	 figure	 3,	 we	 outline	 the	 steps	
required	in	the	development	of	clinically	usable	miR	biomarkers.	Momentum	is	
building	in	technological	development	[40,	41*],	spurred	on	by	the	growing	body	
of	 evidence	 that	 suggests	 miR	 biomarkers	 can	 play	 a	 part	 in	 the	 era	 of	
personalised	medicine.		
	
Key	points	
• miRs	 are	 released	 from	 the	 nephron/urinary	 tract	 and	 may	 be	
detected	 in	 patient	 urine	 at	 a	 time-point	 before	 significant	 renal	
damage	has	occurred	
• We	 predict	 miR	 biomarkers	 will	 enable	 stratification	 of	 renal	
diseases	 in	 a	 purposeful	 way	 that	 is	 amenable	 to	 treatment	
modification	(“personalised	medicine”	approach)	
• Translation	of	miR	biomarkers	into	clinical	use	is	currently	limited	
by	miR	detection	methods	and	the	need	for	 large-scale	validation	
studies	
• Understanding	 the	role	of	miRs	 in	renal	pathophysiology	 is	a	key	
component	 of	 their	 development	 as	 biomarkers,	 which	 in	 turn	
evolves	into	new	therapeutic	target	opportunities	
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Figure	1.	Potential	Uses	of	miR	Biomarkers	in	Nephrology.	MiR	biomarkers	
may	 augment	 our	 current	 ability	 to	 diagnose	 and	 serially	 monitor	 renal	
conditions.	Their	most	useful	application	may	be	in	stratifying	patients	according	
to	 modifiable	 outcomes	 (e.g.	 risk	 of	 developing	 AKI	 or	 CVD)	 or	 providing	 a	
personalised	signature	of	disease	that	may	inform	treatment	decisions	(such	as	
risk	of	renal	allograft	failure	or	likelihood	of	response	to	chemotherapy	agents	in	
renal	 cancers).	 Additionally,	 miRs	 may	 be	 critical	 determinants	 of	 specific	
mechanistic	 pathways	 in	 the	 kidney.	 CVD=cardiovascular	 disease	 RRT=renal	
replacement	therapy	RAAS=	renin-angiotensin-aldosterone	system.	
	
Figure	2.	The	biogenesis	of	urinary	microRNAs.	MiRs	are	released	by	cells	of	
the	nephron	and	downstream	in	the	urinary	tract.	They	may	be	associated	with	
membrane-bound	 extracellular	 vesicles	 such	 as	 microvesicles,	 formed	 by	
outward	 budding	 of	 the	 plasma	 membrane,	 and	 exosomes,	 secreted	 from	
multivesicular	 endosomes	 formed	 in	 the	 endocytic	 tract.	 MiRs	 can	 also	 exist	
bound	 to	 Argonaute	 proteins	 [5]	 and	 other	 proteins	 including	 high-density	
lipoproteins	(HDL)	[6].	
	
	
Figure	 3.	 Phases	 of	 miR	 Biomarker	 Development.	 Initial	 discovery	
experiments	 often	 utilise	 profiling/sequencing	 techniques	 to	 establish	
differentially	 expressed	 microRNAs	 in	 samples	 of	 interest.	 Clinical	 validation	
involves	large	retrospective	and	prospective	cohort	analysis	from	heterogeneous	
populations,	often	achieved	using	(costly)	international	multicentre	studies.	MiR	
detection	assays	and	analysis	platforms	must	be	analytically	validated	to	confirm	
reliability	 and	 reproducibility	 of	 test	 results	 across	 hospital	 settings.	 	 Clinical	
utility	 is	 confirmed	 using	 pre-defined	 patient/treatment	 outcomes,	 but	 for	
complete	integration	into	clinical	practice,	the	test	must	also	be	user-friendly	and	
cost-effective.	 This	 complex	 development	 pathway	 requires	 collaboration	
between	academia,	 industry	and	health	care	services;	 the	predominant	partner	
at	each	stage	is	indicated	above.		
	
 	
Figure	1.	Potential	Uses	of	miR	Biomarkers	in	Nephrology.	MiR	biomarkers	may	augment	our	
current	ability	to	diagnose	and	serially	monitor	renal	conditions,	and	may	potentially	obviate	the	
need	for	invasive	renal	biopsy,	However,	their	most	useful	application	may	be	in	stratifying	
patients	according	to	modifiable	outcomes	(such	as	risk	of	developing	AKI	or	CVD)	or	providing	a	
personalised	signature	of	disease	that	may	inform	treatment	decisions	(such	as	risk	of	renal	
allograft	failure	or	likelihood	of	response	to	chemotherapy	agents	in	renal	cancers).	Additionally,	
miRs	may	be	critical	determinants	of	specific	mechanistic	pathways	that	result	in	changes	to	
renal	architecture	and	physiological	function,	and	can	be	used	as	biomarkers	in	this	context.	
CVD=cardiovascular	disease	RRT=renal	replacement	therapy	RAAS=	renin-angiotensin-
aldosterone	system.	
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Figure	2.	The	biogenesis	of	urinary	microRNAs.	MiRs	are	released	by	cells	of	the	nephron	and	
downstream	in	the	urinary	tract.	They	exist	inside	membrane-bound	vesicles	such	as	
microvesicles,	formed	by	outward	budding	of	the	plasma	membrane,	and	exosomes,	secreted	
from	multivesicular	endosomes	formed	in	the	endocytic	tract.	MiRs	can	also	exist	bound	to	
Argonaute	proteins	(1)	,	but	also	bind	to	other	non-specialised	proteins	such	as	high-density	
lipoproteins	(HDL)	(2).		
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Figure	3.	Phases	of	miR	Biomarker	Development.	Initial	discovery	experiments	often	utilise	
profiling/sequencing	techniques	to	establish	differentially	expressed	microRNAs	in	samples	of	
interest.	Biobanks	are	a	useful	source	in	obtaining	a	validation	cohort	at	this	stage.	Clinical	
validation	involves	large	retrospective	and	prospective	cohort	analysis	from	heterogeneous	
populations,	often	achieved	using	(costly)	international	multicentre	studies.	MiR	detection	assays	
and	analysis	platforms	must	be	analytically	validated	to	confirm	reliability	and	reproducibility	of	
test	results.		Clinical	utility	is	confirmed	using	pre-defined	patient/treatment	outcomes,	but	for	
complete	integration	into	clinical	practice,	the	test	must	also	be	user-friendly	and	cost-effective.	
This	complex	development	pathway	requires	collaboration	between	academia,	industry	and	
health	care	services;	the	predominant	partner	at	each	stage	is	indicated	above.		
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